PFIZER

Pfizer chairman and CEO Albert Bourla said he is taking Pfizer's Paxlovid pill and isolating while he recovers.

Here's our estimate of what Johnson & Johnson's potential exposure to this litigation could be in a worst-case scenario.

When Moderna and Pfizer first came out with their mRNA vaccines for COVID-19, supply was limited to rich countries and they did not share the details of how to create it. That left middle income countries like Brazil in the lurch. But for Brazilian scientists Patricia Neves and Ana Paula Ano Bom, that wasn't the end. They decided to invent their own mRNA vaccine. Their story, today: Aaron talks to global health correspondent Nurith Aizenman about the effort and how it has helped launch a wider global project to revolutionize access to mRNA vaccine technology.

It would be the first major vaccine of its type in 20 years. The companies are seeking thousands of volunteers in the U.S. and Europe as cases keep rising.

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years.

The pharma company’s marketing muscle should boost sales of Global Blood Therapeutics’ medicines to $3 billion a year.

The pharmaceutical giant, which has been on a buying spree, gains one of the few FDA-approved treatments for sickle cell disease with the all-cash deal.

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year.

The following is a transcript of an interview with Dr. Scott Gottlieb, former FDA commissioner and a member of the Pfizer board, that aired Sunday, Aug. 7, 2022, on "Face the Nation."

President Joe Biden experienced a rebound Covid infection after taking Pfizer's antiviral drug Paxlovid. Here's what you need to know about the phenomenon.

The president felt better after taking Paxlovid, but like many others, his infection then rebounded. Why does this keep happening?

U.S. regulators say they are no longer considering authorizing second COVID-19 booster shots for all adults under 50 this summer.

Many scientists believe that updating the vaccines to target omicron BA.4 and BA.5 will provide more durable protection against infection this fall.

U.S. regulators say they are no longer considering authorizing second COVID-19 booster shots for all adults under 50 this summer.

The pharmaceutical company booked net income of $9.9 billion, a 78% increase over the same period during 2021.

Dr. Anthony Fauci says the country's "best guess" for dealing with Covid this fall is a booster shot that targets the BA.5 omicron subvariant. Here's why.

More than 2.7 million courses of Paxlovid pills have been used to date to treat COVID-19 across the country.

President Joe Biden tested positive for COVID-19 on Thursday, underscoring the persistence of the highly contagious virus as new variants challenge the nation's efforts to resume normalcy after two and a half years of pandemic disruptions. White House Press Secretary Karine Jean-Pierre said that Biden was experiencing “mild symptoms" and has begun taking Paxlovid, an antiviral drug designed to reduce the severity of the disease. Biden, 79, is fully vaccinated, after getting two doses of the Pfizer coronavirus vaccine shortly before taking office, a first booster shot in September and an additional dose March 30.

Respiratory-virus season starts basically tomorrow, and our autumn vaccine strategy is shaky at best.

Everyone in Britain who is 50 or over will be offered a fourth dose of coronavirus vaccine in the fall, lowering the age threshold from the previously announced 65.

The U.S. is getting another COVID-19 vaccine choice.

The ever-changing biology of COVID-19 means another booster shot may be necessary to keep people protected.

U.S. pharmacists can now prescribe the leading COVID-19 pill directly to patients.

The fast-changing coronavirus has kicked off summer in the U.S. with lots of infections but relatively few deaths compared to its prior incarnations.

The FDA has given vaccine-makers the green light to develop omicron-specific Covid vaccines. Here's what you should know about those upcoming shots.

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

In a sharply worded dissent Thursday, Justice Clarence Thomas expressed support for the plaintiffs’ debunked claims that all Covid vaccines are made with cells from “aborted children.”

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives.

Advisers to the U.S. government are recommending that COVID-19 booster shots used this fall be modified to better match more recent variants of the coronavirus.

The Food and Drug Administration will have to decide the exact recipe, but a combination shot is expected that adds protection against a version of the omicron variant to the original vaccine.

It is the first time the panel has proposed that vaccine makers modify the shots to target a different variant. The omicron variant is the most dramatic example yet with more than 30 mutations. Pfizer and Moderna developed their omicron shots against the original version of the variant, BA.1. The omicron subvariants BA.4 and BA.5 are now rapidly gaining ground in the U.S. and are poised to become dominant, Marks said. But Dr. Paul Offit, a committee member, said it's unclear whether the immune response data will translate into significant protection in the real world.

Government advisers are debating if Americans should get a modified COVID-19 booster shot this fall — one that better matches more recent virus variants.

Government advisers are debating if Americans should get a modified COVID-19 booster shot this fall — one that better matches more recent virus variants.

The stocks making the biggest moves in premarket trading include Nike, Spirit Airlines, Occidental Petroleum, and more.

U.S. health authorities are facing a critical decision: whether to offer new COVID-19 booster shots this fall that are modified to better match the latest changes of the shape-shifting coronavirus.

These are the stocks posting the largest moves before the bell.

The U.S. Food and Drug Administration is considering ordering a recipe change for the vaccines made by both Pfizer and rival Moderna in hopes that modified boosters could better protect against another surge.

Pfizer's Omicron-only booster sparked the strongest immune response against that variant.

Pfizer said that tweaking its vaccine to better target the omicron variant is safe and works — just days before regulators debate whether to offer Americans updated booster shots this fall.

Pfizer says tweaking its COVID-19 vaccine to better target the omicron variant is safe and boosts protection.

From timing and side effects to choosing between Pfizer and Moderna, here's a primer for parents trying to untangle Covid vaccinations for children under age 5.

Both Pfizer and Moderna are considered safe for kids of all ages, but here are a couple of differences that parents can consider.

Scientists estimate that nearly 20 million lives were saved worldwide by COVID-19 vaccines during their first year.

The White House COVID-19 response team is urging parents to get their young children vaccinated as the country begins to rollout vaccines to the youngest population.

An expert panel backed a second COVID-19 vaccine option for kids ages 6 to 17.

Moderna's request had been stalled for months as regulators studied whether it posed a higher risk of rare heart inflammation side effects.

CDC Director Dr. Rochelle Walensky is expected to sign off on the recommendation later Thursday,.

Georgia's Supreme Court has overturned the murder and child cruelty convictions against a man whose son died after he left him in a hot car for hours. The justices ruled the jury saw evidence that was “extremely and unfairly prejudicial.”

NPR talks to Claire Hannan, who has helped navigate vaccine rollouts in all 50 states, about some of the challenges involved in quickly getting shots out to millions of young kids.

These are the stocks posting the largest moves before the bell.

Will you be vaccinating your child?

U.S. health officials have opened COVID-19 vaccines for infants, toddlers and preschoolers — the last group without the shots.

The CDC committee voted unanimously to recommend the shots for use in infants through preschoolers after two days of meetings that were open to the public.

The vaccinations for children as young as 6 months old could start next week. But first, the Centers for Disease Control and Prevention must sign off.

The FDA's action allows the companies to begin shipping millions of preordered doses across the country.

The FDA's action allows the companies to begin shipping millions of preordered doses across the country.

U.S. regulators on Friday authorized the first COVID-19 shots for infants and preschoolers, paving the way for vaccinations to begin next week.

U.S. regulators have authorized the first COVID-19 shots for infants and preschoolers.

Before shots can be administered to kids as young as 6 months old, the CDC's vaccine advisers are scheduled to vote on updated recommendations this Saturday.

FDA reviewers said both brands, Moderna and Pfizer, appear to be safe and effective for children as young as 6 months old.

COVID-19 shots for infants, toddlers and preschoolers in the U.S. have moved a step closer.

The first COVID-19 shots for infants, toddlers and preschoolers in the U.S. have moved a step closer.

Vaccine effectiveness was estimated at 93% for the teens, and 77% for the younger children, according to the FDA analysis.

Vaccine effectiveness was estimated at 93% for the teens, and 77% for the younger children, according to the FDA analysis.

A government advisory panel has endorsed a second brand of COVID-19 vaccine for school-age children and teens.

A government advisory panel has endorsed a second brand of COVID-19 vaccine for school-age children and teens.

The review from the Food and Drug Administration is a key step toward an expected decision to begin vaccinating babies, toddlers and preschoolers.

The review from the Food and Drug Administration is a key step toward an expected decision to begin vaccinating babies, toddlers and preschoolers.

Next week brings a marathon of hearings as the U.S. decides whether to open COVID-19 vaccinations to kids under 5.

White House officials say pharmacies and states have ordered 1.45 million Pfizer doses and about 850,000 Moderna shots.

The FDA's committee recommended the Novavax vaccine for use in the U.S. on Tuesday.

White House officials say orders have been coming in for COVID-19 vaccine doses for small children.

Now that an FDA advisory committee has recommended the Novavax COVID-19 vaccination for emergency use, experts say we could possibly see the FDA give full approval of the vaccine soon.

A more traditional kind of COVID-19 vaccine is a step closer to becoming the fourth option for U.S. adults.

Novavax was part of the U.S. race to develop a vaccine in 2020, but the company faced manufacturing hurdles that delayed authorization.

The Biden administration says children under 5 may be able to get their first COVID-19 vaccination doses as soon as June 21, if federal regulators authorize shots for the age group as expected.

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries.

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news.

A federal appeals court is being asked to reconsider its decision allowing the Biden administration to require that federal employees get vaccinated against COVID-19.

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5.

The Food and Drug Administration on Tuesday approved children ages 5 to 11 to get a booster dose of Pfizer’s COVID-19 vaccine.

U.S. regulators have authorized a COVID-19 vaccine booster for healthy children ages 5 to 11.

The head of the World Health Organization has called on Pfizer to make its COVID-19 treatment more widely available in poorer countries.

Shares are mixed in Asia with Chinese benchmarks pressing higher after a rally in technology companies helped reverse most of an early slide on Wall Street.

A small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort.

U.S. regulators are strictly limiting who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots.

The Food and Drug Administration has set tentative dates in June to publicly review COVID-19 vaccines for the youngest American children.

COVID-19 patients have two treatment options that can be taken at home.

COVID-19 vaccines still offer strong protection against severe illness and death, but Moderna and Pfizer are testing combination shots as a possible new kind of booster.

Pfizer wants to expand its COVID-19 booster shots to healthy 5- to 11-year-olds.

Germany’s health ministry says the country may have to discard 3 million doses of expired COVID-19 vaccine by the end of June.

A federal appeals court has upheld President Joe Biden’s requirement that all federal employees be vaccinated against COVID-19.

Many Americans can now get a second COVID-19 booster, but it’s hard to tell who really needs another shot right now and who could wait.

A federal judge in Texas is barring the Navy from taking action for now against sailors who've objected to being vaccinated against COVID-19 on religious grounds.

The Food and Drug Administration on Tuesday authorized another COVID-19 booster for people age 50 and older.

Americans age 50 and older can get a second COVID-19 booster if it’s been at least four months since their last vaccination.

The European Union's drug regulator says it has begun an accelerated review process for an experimental coronavirus vaccine booster made by the Spanish company Hipra.

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available.

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers.

Drugmaker Moderna has asked the Food and Drug Administration to authorize a fourth shot of its COVID-19 vaccine as a booster dose for all adults.